| Predicate |
Object |
| contentType |
Journal Article|Review |
| issn |
2050-3377
2050-3369 |
| publicationName |
Arrhythmia & Electrophysiology Review |
| hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_0ea1f39a48fb33a04f3e73f58829b12f |
| bibliographicCitation |
Rordorf R. The ATLAS Randomised Clinical Trial: What do the Superiority Results Mean for Subcutaneous ICD Therapy and Sudden Cardiac Death Prevention as a Whole? Arrhythm Electrophysiol Rev. 2022 Apr;11(). PMID: 36313240; PMCID: PMC9611761. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_40bc727d991b6c76dd443a88a23a26f9 |
| date |
2022-09-05^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://pubmed.ncbi.nlm.nih.gov/PMC9611761
https://pubmed.ncbi.nlm.nih.gov/36313240
https://doi.org/10.15420/aer.2022.11.s1 |
| isPartOf |
https://portal.issn.org/resource/ISSN/2050-3377
https://portal.issn.org/resource/ISSN/2050-3369
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/44720 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
The ATLAS Randomised Clinical Trial: What do the Superiority Results Mean for Subcutaneous ICD Therapy and Sudden Cardiac Death Prevention as a Whole? |